Combined radioligand therapy and immunotherapy for cancer: research advances and translational challenges
Sen Wang, Shoujun Tang, Shengjie Tang, Chun Wang, Junjie Wang, Yunlong Yang, Yang Yang, Chengkuan Liu, Jiang Fu, Haining Zhou · 2026
Read Combined radioligand therapy and immunotherapy for cancer: research advances and translational challenges by Sen Wang, Shoujun Tang, Shengjie Tang, Chun Wang, Junjie Wang, Yunlong Yang, Yang Yang, Chengkuan Liu, Jiang Fu, Haining Zhou (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13618075.txt.
Description
Sen Wang, Haining Zhou, and eight co-authors review pairing targeted radiation with immunotherapy for cancer. Their review, from twenty twenty-six, covers radioligand therapy. A tagged molecule carries a radioactive payload straight to tumor targets. The method already serves prostate and nerve-type tumors well in clinics.
Radiation kills tumor cells directly, but it may also wake the immune system. Dying cells spill signals that help immune cells spot the tumor. Checkpoint drugs then free T cells to attack. Lab models show the pair can outdo either alone. Human proof is still early, the authors stress. Their review follows the chain from mechanism to clinic.
Catalog record
| CREATOR | Sen Wang, Shoujun Tang, Shengjie Tang, Chun Wang, Junjie Wang, Yunlong Yang, Yang Yang, Chengkuan Liu, Jiang Fu, Haining Zhou |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |